Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

49.37 -1.20 (-2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,742
Open 49.81
Bid (Size) 48.65 (1)
Ask (Size) 50.83 (1)
Prev. Close 50.57
Today's Range 48.94 - 50.33
52wk Range 37.82 - 71.32
Shares Outstanding 60,664,749
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66  
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga

Performance

YTD
+14.02%
+14.02%
1 Month
+0.06%
+0.06%
3 Month
-22.96%
-22.96%
6 Month
+13.21%
+13.21%
1 Year
-27.49%
-27.49%

More News

Read More
What 15 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
Via The Motley Fool
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
3 Biotech Stocks Using AI to Change Healthcare Forever
Via InvestorPlace
Analyst Ratings for Blueprint Medicines
Via Benzinga
What Will AbbVie Buy Next?
Via The Motley Fool
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
ETF Returns: Mid-Cap Winners And Losers
Via Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
Via InvestorPlace
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Via The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.